General Blog

$13 million new funding for Akili’s innovative ADHD therapy

555 0

Image result for $13 million new funding for Akili’s innovative ADHD therapy

Boston-based Akili Interactive receives another $13 million as an extension of its Series C funding round. The funds from Akili’s latest funding round will advance its digital medicine platform, delivering novel treatments for cognitive dysfunction and brain related conditions.

Akili’s proprietary technology platform means more than a single product; it is an entirely new category of digital medicine, one with world-renowned cognitive neuroscientists and entertainment and technology designers as “parents.”

Akili’s products deliver certain stimuli destined to specifically target and activate brain cognitive neural systems which are affected by medical conditions across neurology and psychiatry. Akili’s delivery method is a very inventive one. The company is pioneering software based prescription digital medicine that not only uses adaptive algorithms to treat a disorder but also feels like a video game.

In December 2017, Akili announced positive top-line results of a multi-center, randomized, double-blind, controlled pivotal study which had as purpose the evaluation of AKL-T01’s safety and efficacy. If cleared by FDA, AKL-T01 would be the first prescription video game to treat a medical condition and the first prescription digital medicine for children with ADHD.

According to the American Psychiatric Association, attention-deficit/hyperactivity disorder (ADHD) is one of the most common mental disorders affecting children, but also adults. Symptoms include lack of attention, hyperactivity, and impulsivity.

This new treatment could become a hit, especially since its presentation is so user-friendly. It would become another great example that speaks to the digital transformation of healthcare by developing out-of-the-box therapies for patients in need.

Both Akili’s officials and investors have faith in the company’s future, as well as the future of digital medicine. Patients, parents, educators, and medical staff are now waiting to see if this new therapy makes it to market.  

Check out the list of innovative healthcare startups to watch in 2018